Condition

Minimal Change Disease clinical trials and research

• 10Clinical trials
• 2NIH research projects
• 13Countries

Newest Minimal Change Disease clinical trials

All recruiting trials (10)

• Testing ManNAc for treating kidney disease FSGS

  This study is testing if a new oral treatment called ManNAc can help adults with kidney disease FSGS by reducing protein levels in their urine and checking how safe it is over 12 weeks.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06664814

• Evaluating WAL0921 for kidney diseases

  This study is testing a new drug called WAL0921 to see if it can help people with different types of kidney diseases feel better.

  Recruiting at 25 sites Phase 2 Walden Biosciences · Los Angeles, California and 49 other locations · NCT06466135

• Observational study on kidney transplant recurrence in FSGS and MCD

  This study is looking at patients with kidney diseases called FSGS and MCD who have had or will have a kidney transplant to see how often these diseases come back afterward.

  Recruiting University of Michigan · Ann Arbor, Michigan · NCT05650619

• Vagus nerve stimulation for treating nephrotic syndrome in children

  This study is testing whether a new treatment using vagus nerve stimulation can help children aged 3 to 17 with nephrotic syndrome feel better and reduce their symptoms.

  Recruiting at 2 sites Northwell Health · New Hyde Park, New York and 1 other locations · NCT05588063

• Using vagus nerve stimulation to treat nephrotic syndrome in children

  This study is testing if a new type of nerve stimulation can help children with steroid-resistant nephrotic syndrome feel better over 26 weeks.

  Recruiting at 2 sites Northwell Health · New Hyde Park, New York and 1 other locations · NCT05583942

• Exploring experiences of patients and parents dealing with swelling from Nephrotic Syndrome

  This study talks to patients and parents about their experiences with swelling from Nephrotic Syndrome to help create better ways to measure how new treatments work.

  Recruiting University of Michigan · Ann Arbor, Michigan · NCT05505500

• Treatment of pediatric kidney diseases with Sparsentan

  This study is testing if a new oral medication called Sparsentan can help children aged 1 to 18 with certain kidney diseases feel better and improve their condition over two years.

  Recruiting at 38 sites Phase 2 Travere Therapeutics, Inc. · Los Angeles, California and 46 other locations · NCT05003986

• NEPTUNE Match: Personalized matching of patients to kidney treatment options

  This project will try a system that matches people in the NEPTUNE cohort who have nephrotic syndromes or related kidney diseases with suitable clinical trials and shares those matches with patients and their doctors.

  Recruiting at 15 sites University of Michigan · Atlanta, Georgia and 15 other locations · NCT04571658

• Registry for patients with Focal Segmental Glomerulosclerosis and Minimal Change Disease

  This study is setting up a registry to collect health information and samples from kids and adults with certain kidney diseases to help researchers learn more about them and improve treatments.

  Recruiting at 10 sites University of Cologne · Cologne, North Rhine-Westphalia and 11 other locations · NCT03949972

• A network for analyzing kidney biopsy data in glomerular diseases

  This study is trying to build a detailed database of kidney biopsy samples and health information from patients with glomerular diseases to help researchers better understand these conditions and improve treatments.

  Recruiting at 6 sites Seoul National University Hospital · Chuncheon and 5 other locations · NCT03929887

NIH-funded research (2)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• How the AMPK energy-sensor affects whether minimal change disease becomes FSGS

  This work looks at how a cell energy sensor called AMPK helps protect kidney filter cells and whether that keeps people with minimal change disease from progressing to focal segmental glomerulosclerosis.

  NIH research Yale University · New Haven, United States · NIH-11235113

• Investigating how AMP-kinase affects kidney disease transitions

  This study is looking at how certain proteins in the kidneys affect the health of important cells called podocytes, which can help us understand why some people with nephrotic syndrome go from having a mild form of the disease to a more serious one, and it involves both human samples and mice to find ways to keep these

  NIH research Yale University · New Haven, United States · NIH-10978223

Related topics

Quick answers

How many Minimal Change Disease clinical trials are recruiting right now?

10, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 13 countries. The most sites are in United States (8 trials), Germany (2 trials), United Kingdom (2 trials), South Korea (2 trials), Italy (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →